Matches in DBpedia 2016-04 for { <http://dbpedia.org/resource/CimaVax-EGF> ?p ?o }
Showing triples 1 to 47 of
47
with 100 triples per page.
- CimaVax-EGF abstract "CimaVax-EGF is the first therapeutic cancer vaccine developed to target non-small-cell lung carcinoma (NSCLC), the most common form of lung cancer. The vaccine was the result of a 25-year research project at Cuba’s Center of Molecular Immunology. The product has gone through 2 trial phases in Cuba and is currently in the process of going through a third trial, and there are agreements in place to test it in the United States (at Roswell Park Cancer Institute, subject to approval of an Investigational New Drug by the U.S. Food and Drug Administration), Japan, and some European countries. It is currently only available in Cuba. In October 2015 Serbian Institute of Virology Torlak signed memorandum for a full medical treatment of 30 patients that will be part of a clinical study. CimaVax is relatively cheap to produce and store, and has low toxicity. Side effects of the vaccine appear to be mild, and include chills, fever, and feeling sick.".
- CimaVax-EGF wikiPageID "34024745".
- CimaVax-EGF wikiPageLength "7249".
- CimaVax-EGF wikiPageOutDegree "26".
- CimaVax-EGF wikiPageRevisionID "706582118".
- CimaVax-EGF wikiPageWikiLink Adjuvant.
- CimaVax-EGF wikiPageWikiLink Aluminium_hydroxide.
- CimaVax-EGF wikiPageWikiLink Antibody.
- CimaVax-EGF wikiPageWikiLink Cancer_vaccine.
- CimaVax-EGF wikiPageWikiLink Category:Cancer_vaccines.
- CimaVax-EGF wikiPageWikiLink Category:Cuban_inventions.
- CimaVax-EGF wikiPageWikiLink Category:Health_in_Cuba.
- CimaVax-EGF wikiPageWikiLink Center_of_Molecular_Immunology.
- CimaVax-EGF wikiPageWikiLink Chemotherapy.
- CimaVax-EGF wikiPageWikiLink Cuba.
- CimaVax-EGF wikiPageWikiLink Cyclophosphamide.
- CimaVax-EGF wikiPageWikiLink Epidermal_growth_factor.
- CimaVax-EGF wikiPageWikiLink Epidermal_growth_factor_receptor.
- CimaVax-EGF wikiPageWikiLink Food_and_Drug_Administration.
- CimaVax-EGF wikiPageWikiLink Immune_tolerance.
- CimaVax-EGF wikiPageWikiLink Investigational_New_Drug.
- CimaVax-EGF wikiPageWikiLink Ligand.
- CimaVax-EGF wikiPageWikiLink Lung_cancer.
- CimaVax-EGF wikiPageWikiLink Montanide_ISA_51.
- CimaVax-EGF wikiPageWikiLink Neisseria_meningitidis.
- CimaVax-EGF wikiPageWikiLink Non-small-cell_lung_carcinoma.
- CimaVax-EGF wikiPageWikiLink P64k.
- CimaVax-EGF wikiPageWikiLink Prostate_cancer.
- CimaVax-EGF wikiPageWikiLink Roswell_Park_Cancer_Institute.
- CimaVax-EGF wikiPageWikiLink Serbia.
- CimaVax-EGF wikiPageWikiLink Vaccine.
- CimaVax-EGF wikiPageWikiLinkText "CimaVax-EGF".
- CimaVax-EGF wikiPageWikiLinkText "Cimavax".
- CimaVax-EGF wikiPageUsesTemplate Template:Reflist.
- CimaVax-EGF subject Category:Cancer_vaccines.
- CimaVax-EGF subject Category:Cuban_inventions.
- CimaVax-EGF subject Category:Health_in_Cuba.
- CimaVax-EGF hypernym Vaccine.
- CimaVax-EGF type Drug.
- CimaVax-EGF comment "CimaVax-EGF is the first therapeutic cancer vaccine developed to target non-small-cell lung carcinoma (NSCLC), the most common form of lung cancer. The vaccine was the result of a 25-year research project at Cuba’s Center of Molecular Immunology.".
- CimaVax-EGF label "CimaVax-EGF".
- CimaVax-EGF sameAs Q5120048.
- CimaVax-EGF sameAs CimaVax-EGF.
- CimaVax-EGF sameAs m.0hr3y6z.
- CimaVax-EGF sameAs Q5120048.
- CimaVax-EGF wasDerivedFrom CimaVax-EGF?oldid=706582118.
- CimaVax-EGF isPrimaryTopicOf CimaVax-EGF.